Decision Diagnostics Corp. Logo

Decision Diagnostics Corp.

DECN

(0.8)
Stock Price

0,00 USD

0% ROA

0% ROE

0x PER

Market Cap.

35.450,00 USD

0% DER

0% Yield

0% NPM

Decision Diagnostics Corp. Stock Analysis

Decision Diagnostics Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Decision Diagnostics Corp. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

2 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-10388.57%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-938.01%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 DER

The company has a high debt to equity ratio (583%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Decision Diagnostics Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Decision Diagnostics Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Decision Diagnostics Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Decision Diagnostics Corp. Revenue
Year Revenue Growth
2001 940.621
2002 2.000 -46931.05%
2003 75.813 97.36%
2004 182.112 58.37%
2005 5.614.313 96.76%
2006 19.220.265 70.79%
2007 6.254.278 -207.31%
2008 14.953.356 58.17%
2009 19.607.230 23.74%
2010 18.913.712 -3.67%
2011 12.112.093 -56.16%
2012 6.197.691 -95.43%
2015 292.033 -2022.26%
2016 725.484 59.75%
2017 1.880.391 61.42%
2018 2.235.989 15.9%
2019 2.379.234 6.02%
2020 1.979.159 -20.21%
2021 2.074.044 4.57%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Decision Diagnostics Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Decision Diagnostics Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 783.919 100%
2009 661.665 -18.48%
2010 852.353 22.37%
2011 3.883.334 78.05%
2012 3.510.827 -10.61%
2015 2.704.442 -29.82%
2016 3.164.971 14.55%
2017 2.230.896 -41.87%
2018 2.101.334 -6.17%
2019 1.728.207 -21.59%
2020 2.309.692 25.18%
2021 2.221.952 -3.95%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Decision Diagnostics Corp. EBITDA
Year EBITDA Growth
2001 -171.731
2002 -1.856.940 90.75%
2003 -1.765.487 -5.18%
2004 -1.321.188 -33.63%
2005 -1.724.136 23.37%
2006 -1.834.308 6.01%
2007 -1.005.752 -82.38%
2008 694.594 244.8%
2009 -427.861 262.34%
2010 1.395.259 130.67%
2011 -381.300 465.92%
2012 -2.706.968 85.91%
2015 -298.284 -807.51%
2016 -168.215 -77.32%
2017 -526.223 68.03%
2018 -1.853.160 71.6%
2019 -1.294.382 -43.17%
2020 -2.101.432 38.4%
2021 -1.962.888 -7.06%
2021 0 0%
2022 0 0%
2023 0 0%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Decision Diagnostics Corp. Gross Profit
Year Gross Profit Growth
2001 358.478
2002 2.000 -17823.9%
2003 75.813 97.36%
2004 182.112 58.37%
2005 501.684 63.7%
2006 34.028 -1374.33%
2007 408.496 91.67%
2008 1.478.513 72.37%
2009 1.579.671 6.4%
2010 1.636.654 3.48%
2011 2.876.041 43.09%
2012 1.523.145 -88.82%
2015 169.064 -800.93%
2016 248.766 32.04%
2017 -69.659 457.12%
2018 307.197 122.68%
2019 850.352 63.87%
2020 498.450 -70.6%
2021 461.116 -8.1%
2021 0 0%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Decision Diagnostics Corp. Net Profit
Year Net Profit Growth
2001 -488.750
2002 -1.970.158 75.19%
2003 -2.168.808 9.16%
2004 -4.551.027 52.34%
2005 -4.823.308 5.65%
2006 -2.754.810 -75.09%
2007 -1.409.779 -95.41%
2008 187.773 850.79%
2009 1.684.356 88.85%
2010 -471.837 456.98%
2011 -2.117.006 77.71%
2012 -3.081.497 31.3%
2015 -2.206.168 -39.68%
2016 -2.967.357 25.65%
2017 -2.991.404 0.8%
2018 -2.240.220 -33.53%
2019 -3.132.295 28.48%
2020 -29.668.622 89.44%
2021 -2.219.688 -1236.61%
2021 0 0%
2022 0 0%
2023 0 0%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Decision Diagnostics Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 -26
2002 -46 45.65%
2003 -23 -100%
2004 -23 -4.55%
2005 -11 -120%
2006 -4 -150%
2007 -1 -300%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Decision Diagnostics Corp. Free Cashflow
Year Free Cashflow Growth
2001 115.668
2002 -603.899 119.15%
2003 -466.276 -29.52%
2004 -917.184 49.16%
2005 -2.402.564 61.82%
2006 -991.710 -142.26%
2007 -785.887 -26.19%
2008 -1.006.995 21.96%
2009 -183.240 -449.55%
2010 -609.767 69.95%
2011 -268.275 -127.29%
2012 -40.991 -554.47%
2015 -1.514.423 97.29%
2016 -2.847.871 46.82%
2017 -1.673.553 -70.17%
2018 -1.413.246 -18.42%
2019 -1.231.046 -14.8%
2020 -1.404.973 12.38%
2021 0 0%
2021 -62.090 100%
2022 0 0%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Decision Diagnostics Corp. Operating Cashflow
Year Operating Cashflow Growth
2001 127.637
2002 -603.899 121.14%
2003 -466.276 -29.52%
2004 -917.184 49.16%
2005 -2.402.564 61.82%
2006 -991.710 -142.26%
2007 -785.887 -26.19%
2008 -1.006.995 21.96%
2009 -183.240 -449.55%
2010 -599.817 69.45%
2011 -208.690 -187.42%
2012 9.884 2211.39%
2015 -1.028.781 100.96%
2016 -2.530.121 59.34%
2017 -1.558.918 -62.3%
2018 -1.322.946 -17.84%
2019 -1.114.671 -18.68%
2020 -1.404.973 20.66%
2021 0 0%
2021 -60.465 100%
2022 0 0%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Decision Diagnostics Corp. Capital Expenditure
Year Capital Expenditure Growth
2001 11.969
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 9.950 100%
2011 59.585 83.3%
2012 50.875 -17.12%
2015 485.642 89.52%
2016 317.750 -52.84%
2017 114.635 -177.18%
2018 90.300 -26.95%
2019 116.375 22.41%
2020 0 0%
2021 0 0%
2021 1.625 100%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Decision Diagnostics Corp. Equity
Year Equity Growth
2001 222.525
2002 1.049.321 78.79%
2003 77.886 -1247.25%
2004 -330.228 123.59%
2005 -147.688 -123.6%
2006 -2.231.555 93.38%
2007 -2.030.030 -9.93%
2008 -1.319.517 -53.85%
2009 1.286.859 202.54%
2010 2.367.558 45.65%
2011 1.869.767 -26.62%
2012 851.580 -119.56%
2015 579.073 -47.06%
2016 2.441.123 76.28%
2017 1.721.858 -41.77%
2018 1.174.341 -46.62%
2019 87.584 -1240.82%
2020 483.594 81.89%
2021 0 0%
2021 -52.130 100%
2022 0 0%
2023 0 0%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Decision Diagnostics Corp. Assets
Year Assets Growth
2001 1.511.471
2002 1.545.426 2.2%
2003 749.561 -106.18%
2004 914.440 18.03%
2005 1.336.989 31.6%
2006 373.055 -258.39%
2007 813.322 54.13%
2008 2.870.624 71.67%
2009 4.324.237 33.62%
2010 5.066.835 14.66%
2011 4.607.484 -9.97%
2012 4.141.465 -11.25%
2015 3.436.291 -20.52%
2016 6.306.079 45.51%
2017 5.215.002 -20.92%
2018 4.268.823 -22.16%
2019 5.305.074 19.53%
2020 5.653.742 6.17%
2021 0 0%
2021 5.342.983 100%
2022 0 0%
2023 0 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Decision Diagnostics Corp. Liabilities
Year Liabilities Growth
2001 1.288.946
2002 496.105 -159.81%
2003 671.675 26.14%
2004 1.244.668 46.04%
2005 1.484.677 16.17%
2006 2.604.610 43%
2007 2.843.352 8.4%
2008 4.190.141 32.14%
2009 3.037.378 -37.95%
2010 2.699.277 -12.53%
2011 2.737.717 1.4%
2012 3.289.885 16.78%
2015 2.857.218 -15.14%
2016 3.864.956 26.07%
2017 3.493.143 -10.64%
2018 3.094.481 -12.88%
2019 5.217.490 40.69%
2020 5.170.148 -0.92%
2021 0 0%
2021 5.395.113 100%
2022 0 0%
2023 0 0%

Decision Diagnostics Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0
Price to Earning Ratio
0x
Price To Sales Ratio
0x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
0
EV to Sales
0
EV Over EBITDA
0
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
0
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0
Graham NetNet
0

Income Statement Metrics

Net Income per Share
0
Income Quality
0
ROE
0
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Decision Diagnostics Corp. Dividends
Year Dividends Growth

Decision Diagnostics Corp. Profile

About Decision Diagnostics Corp.

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.

CEO
Mr. Keith M. Berman
Employee
6
Address
2660 Townsgate Road
Westlake Village, 91361

Decision Diagnostics Corp. Executives & BODs

Decision Diagnostics Corp. Executives & BODs
# Name Age
1 Mr. Keith M. Berman
Chief Executive Officer, Chief Financial Officer, Secretary & Director
70
2 Mr. Mark Krakauer
Head of Genstrip Private Label Sales Efforts
70

Decision Diagnostics Corp. Competitors